Compare KGS & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | SYRE |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.0B |
| IPO Year | 2023 | 2015 |
| Metric | KGS | SYRE |
|---|---|---|
| Price | $62.15 | $69.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $55.67 | ★ $82.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ 58.93 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $1,308,100,000.00 | N/A |
| Revenue This Year | $11.61 | N/A |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | $69.24 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $30.06 | $12.29 |
| 52 Week High | $63.62 | $75.00 |
| Indicator | KGS | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 69.05 | 84.30 |
| Support Level | $56.51 | $15.23 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.67 | 4.18 |
| MACD | 0.08 | 2.07 |
| Stochastic Oscillator | 79.75 | 82.25 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.